Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab for advanced solid tumors (prospective multicenter observational)
ChiCTR2000038489Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in advanced nonhematological malignancy, sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoints: Progression-free survival (PFS) and Incidence of adverse events (AEs). Started Nov 2020; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
advanced nonhematological malignancy
Beyond the preview
Go deeper on ChiCTR2000038489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038489.